Headline News

WASHINGTON — Inebilizumab is safe and effective in IgG4-related disease, significantly reducing the chance of flare through 52 weeks compared with placebo, according to data presented at ACR Convergence 2024.

CHICAGO — When the American Heart Association was founded by six clinicians in June 1924, there was no treatment — and little hope — for people living with heart disease.

CHICAGO — A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin reduced transthyretin levels in patients with cardiac amyloidosis, researchers reported at the American Heart Association Scientific Sessions.

CHICAGO — An intensive blood pressure strategy resulted in a lower incidence of major cardiovascular events compared with a more standard strategy among patients with type 2 diabetes and elevated systolic blood pressure in the BPROAD trial.

NEW YORK — In this Healio Video Perspective from OSN New York, Nathan M. Radcliffe, MD, discusses interventional glaucoma management.

WASHINGTON — Whether through advocacy on Capitol Hill, helping women advance their careers, or addressing the rheumatology workforce shortage, American College of Rheumatology President Deborah Dyett Desir, MD, believes in “giving back.”

WASHINGTON — Despite the heated “rhetoric” regarding diversity, equity and inclusion efforts, the idea that predominantly white organizations are resentful of DEI programs is incorrect, according to the ACR Convergence 2024 keynote speaker.

CHICAGO — In adults with HF with preserved ejection fraction and obesity, treatment with tirzepatide cut risk for CV death or worsening HF by 38% compared with placebo, with a parallel improvement in health status and exercise tolerance.

The FDA has accepted the resubmission of the supplemental biologics license application for Dupixent to treat chronic spontaneous urticaria in adults and children, Regeneron Pharmaceutical and Sanofi announced in a press release.

Corin has received FDA 510(k) clearance of its Icona femoral stem for direct anterior total hip arthroplasty with design considerations for use in the ASC setting, according to a press release.